CA2457541C - Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders - Google Patents

Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders Download PDF

Info

Publication number
CA2457541C
CA2457541C CA2457541A CA2457541A CA2457541C CA 2457541 C CA2457541 C CA 2457541C CA 2457541 A CA2457541 A CA 2457541A CA 2457541 A CA2457541 A CA 2457541A CA 2457541 C CA2457541 C CA 2457541C
Authority
CA
Canada
Prior art keywords
antibody
proliferating
cell
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2457541A
Other languages
English (en)
French (fr)
Other versions
CA2457541A1 (en
Inventor
Arthur D. Levinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2457541A1 publication Critical patent/CA2457541A1/en
Application granted granted Critical
Publication of CA2457541C publication Critical patent/CA2457541C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2457541A 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders Expired - Fee Related CA2457541C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31750401P 2001-09-05 2001-09-05
US60/317,504 2001-09-05
PCT/US2002/028176 WO2003020909A2 (en) 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders

Publications (2)

Publication Number Publication Date
CA2457541A1 CA2457541A1 (en) 2003-03-13
CA2457541C true CA2457541C (en) 2013-01-08

Family

ID=23233944

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2457541A Expired - Fee Related CA2457541C (en) 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders

Country Status (17)

Country Link
EP (1) EP1432446B1 (pl)
JP (2) JP5224632B2 (pl)
KR (3) KR20100061863A (pl)
CN (2) CN1578673A (pl)
AT (1) ATE506965T1 (pl)
AU (1) AU2002332838B2 (pl)
BR (1) BR0212641A (pl)
CA (1) CA2457541C (pl)
DE (1) DE60239881D1 (pl)
DK (1) DK1432446T3 (pl)
HU (1) HUP0500617A3 (pl)
IL (2) IL160659A0 (pl)
MX (1) MXPA04002084A (pl)
NZ (1) NZ531515A (pl)
PL (1) PL374363A1 (pl)
WO (1) WO2003020909A2 (pl)
ZA (1) ZA200401751B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101145506B1 (ko) * 2003-05-20 2012-05-15 이뮤노젠 아이엔씨 새로운 메이탠시노이드를 포함하는 개선된 세포독성체
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NO347360B1 (no) * 2003-10-10 2023-09-25 Immunogen Inc Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse.
HUE029925T2 (en) * 2008-04-02 2017-04-28 Macrogenics Inc HER2 / neu-specific antibodies and methods using them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
BR0015224A (pt) * 1999-10-29 2002-07-09 Genentech Inc Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
CA2397416A1 (en) * 2000-01-26 2001-08-02 Jonathan Cohen A system for developing assays for personalized medicine

Also Published As

Publication number Publication date
NZ531515A (en) 2007-11-30
IL160659A0 (en) 2004-08-31
BR0212641A (pt) 2005-04-12
KR20090104925A (ko) 2009-10-06
HUP0500617A2 (hu) 2005-10-28
WO2003020909A3 (en) 2003-11-20
EP1432446A4 (en) 2004-09-08
MXPA04002084A (es) 2004-06-07
CN1578673A (zh) 2005-02-09
JP5224632B2 (ja) 2013-07-03
EP1432446B1 (en) 2011-04-27
HUP0500617A3 (en) 2012-05-02
EP1432446A2 (en) 2004-06-30
CN101446590A (zh) 2009-06-03
ATE506965T1 (de) 2011-05-15
KR20040044850A (ko) 2004-05-31
ZA200401751B (en) 2005-07-27
KR20100061863A (ko) 2010-06-09
DE60239881D1 (de) 2011-06-09
AU2002332838B2 (en) 2007-08-02
JP2005517155A (ja) 2005-06-09
CA2457541A1 (en) 2003-03-13
DK1432446T3 (da) 2011-07-18
WO2003020909A2 (en) 2003-03-13
PL374363A1 (pl) 2005-10-17
JP2010280691A (ja) 2010-12-16
IL160659A (en) 2011-07-31

Similar Documents

Publication Publication Date Title
US20040235068A1 (en) Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
CA2490758C (en) Dosage form of recombinant humanized monoclonal antibody 2c4
US20080124739A1 (en) Compositions and methods for the diagnosis and treatment of tumor
US20090304689A1 (en) Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
JP2008500949A (ja) 腫瘍の診断と治療のための組成物と方法
JP2010280691A (ja) 細胞増殖異常に伴う疾患に関連するポリペプチド抗原の同定方法及びそのような疾患の治療に有効な組成物
AU2002332838A1 (en) Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
JP2008505182A (ja) 非ホジキンリンパ腫の治療のための組成物と方法
US20080193446A1 (en) Compositions and Methods for the Diagnosis and Treatment of Tumor
KR20080003405A (ko) 종양의 진단 및 치료를 위한 조성물 및 방법
CA2678555A1 (en) Amelioration of cellular stress response
HK1143746A (en) Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170905